OTARMENI / Lunsotogene parvec-cwha for biallelic OTOF variant–associated hearing loss

As of September 2026, MARA’s assessment finds OTARMENI / Lunsotogene parvec-cwha’s reimbursement risk concentrated in comparator selection, with care pathway integration a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs clinical effectiveness: how much additional benefit the drug demonstrated over the care patients already receive — the first question every payer asks. The strength recorded in care pathway integration carries weight because that domain asks how the drug fits into the way care is organised today; a treatment that demands new infrastructure or displaces an established pathway faces extra scrutiny.

Neurology

This rating sits within MARA’s Neurology coverage, alongside 65 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

The evidence shows a substantial hearing-sensitivity effect in pediatric patients, but lacks a randomized comparison against standard of care, such as cochlear implantation. The absence of a concurrent SOC arm is a major limitation.

Does the economic case hold at the expected price? — Cost effectiveness

No peer-reviewed cost-effectiveness analysis or public HTA economic model reporting incremental cost for OTARMENI versus CI was identified.

Is there quality-of-life evidence payers weigh? — Quality of life

No product-specific results using validated HRQoL instruments were identified, and FDA’s postmarketing requirement calls for quality-of-life scales, indicating that HRQoL evidence is insufficient.

Does the safety profile hold up for payers? — Safety and Adverse Effects

The safety profile is acceptable with most adverse events being mild or moderate. However, the small sample size limits the ability to assess rare or long-term safety events.

Was the drug compared against what payers expect? — Comparator Selection

The formal study lacks a concurrent comparator, and the real-world treatment alternative is cochlear implantation, which was not directly compared.

Is the population defined the way payers need it? — Patient Population and Subgroups

The study population is narrower than the full spectrum of biallelic OTOF disease, with evidence most direct for children with typical profound OTOF disease. Adult treatment is extrapolated from pediatric data.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

The treatment requires specialized centers and specific diagnostic processes, but these are well defined. However, the broader population-scale capacity and resource impact are not yet published.

Are the wider system costs understood? — Resource Use and Cost Implications

No published total episode-of-care cost or direct observed cost comparison against CI is available.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The study is open-label and single-arm, with regulatory flexibility accepted by FDA. The absence of randomization and concurrent CI comparison lowers certainty for comparative patient benefit.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty exists due to the lack of long-term data, adult outcomes, and comparative effectiveness versus CI. FDA’s postmarketing requirements align with these uncertainties.

This rating replaces the earlier August 2026 rating of the same drug and indication — still on the record here.

Request the current rating

Be alerted when this rating changes:

Related Reimbursement Risk Assessments

Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.